|Bid||36.56 x 1800|
|Ask||36.57 x 2900|
|Day's range||36.48 - 36.81|
|52-week range||26.45 - 43.08|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||23.75|
|Earnings date||02 Feb 2021|
|Forward dividend & yield||1.56 (4.25%)|
|Ex-dividend date||28 Jan 2021|
|1y target est||41.79|
U.S. hits 400,000 deaths as virus spread continues to overwhelm parts of the country. Meanwhile, vaccine chaos hampers efforts.
Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.
Ireland looks to get ahead by securing AstraZeneca vaccine supply before EMA recommendation. Others could follow suit with supply a constraint.